26 December 2016
designer natriuretic peptide, drug development, heart failure, hypertension, natriuretic peptide, ANP, A-type natriuretic peptide, AS-BNP, alternatively spliced variant of BNP, BNP, B-type natriuretic peptide, BP, blood pressure, CD-NP, cenderitide, cGMP, cyclic guanosine monophosphate, CNP, C-type natriuretic peptide, CV, cardiovascular, DNP, D-type natriuretic peptide, FDA, Food and Drug Administration, GFR, glomerular filtration rate, HF, heart failure, HTN, hypertension, NEP, neprilysin, NP, natriuretic peptide, NPR, natriuretic peptide receptor, pGC, particulate guanylyl cyclase, RAAS, renin-angiotensin-aldosterone system, SQ, subcutaneous, URO, urodilatin, VNP, ventricular natriuretic peptide, ZD100, MANP
Natriuretic peptides (NPs) are essential for the maintenance of volume homeostasis, and can be of myocardial, renal, and endothelial origin. Advances in peptide engineering have enabled the design of innovative designer NPs that go beyond native peptides in efficacy, specificity, and resistance to enzymatic degradation. Therefore, designer NPs provide an unparalleled opportunity for the treatment of cardiovascular disease. In this review, we report the conceptual framework of peptide engineering of the NPs that resulted in designer peptides for cardiovascular disease. We specifically provide an update on those currently in clinical trials for heart failure and hypertension.